The Insulin:Glucagon Ratio and the Choice of Glucose-Lowering Drugs

The influence of alpha and beta cells, through glucagon and insulin, on energy metabolism is well known. The insulin:glucagon ratio (IGR) is a frequently discussed entity in the medical literature. However, in recent years, focus has shifted to other pathways and markers of health and disease. This...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalra, Sanjay, Gupta, Yashdeep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4801814/
https://www.ncbi.nlm.nih.gov/pubmed/26965024
http://dx.doi.org/10.1007/s13300-016-0160-4
_version_ 1782422618692911104
author Kalra, Sanjay
Gupta, Yashdeep
author_facet Kalra, Sanjay
Gupta, Yashdeep
author_sort Kalra, Sanjay
collection PubMed
description The influence of alpha and beta cells, through glucagon and insulin, on energy metabolism is well known. The insulin:glucagon ratio (IGR) is a frequently discussed entity in the medical literature. However, in recent years, focus has shifted to other pathways and markers of health and disease. This communication revisits the insulin:glucagon bipolar axis and describes the significance of the IGR. It reviews the effects of various glucose-lowering drugs on this ratio, and hypothesizes that the ratio can be used to predict the appropriate choice of drugs for managing diabetes. Drugs which increase the IGR may be beneficial in insulinopenic conditions, while those which decrease IGR may be of help in the setting of hyperinsulinemia or insulin resistance.
format Online
Article
Text
id pubmed-4801814
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-48018142016-04-06 The Insulin:Glucagon Ratio and the Choice of Glucose-Lowering Drugs Kalra, Sanjay Gupta, Yashdeep Diabetes Ther Commentary The influence of alpha and beta cells, through glucagon and insulin, on energy metabolism is well known. The insulin:glucagon ratio (IGR) is a frequently discussed entity in the medical literature. However, in recent years, focus has shifted to other pathways and markers of health and disease. This communication revisits the insulin:glucagon bipolar axis and describes the significance of the IGR. It reviews the effects of various glucose-lowering drugs on this ratio, and hypothesizes that the ratio can be used to predict the appropriate choice of drugs for managing diabetes. Drugs which increase the IGR may be beneficial in insulinopenic conditions, while those which decrease IGR may be of help in the setting of hyperinsulinemia or insulin resistance. Springer Healthcare 2016-03-10 2016-03 /pmc/articles/PMC4801814/ /pubmed/26965024 http://dx.doi.org/10.1007/s13300-016-0160-4 Text en © The Author(s) 2016 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Commentary
Kalra, Sanjay
Gupta, Yashdeep
The Insulin:Glucagon Ratio and the Choice of Glucose-Lowering Drugs
title The Insulin:Glucagon Ratio and the Choice of Glucose-Lowering Drugs
title_full The Insulin:Glucagon Ratio and the Choice of Glucose-Lowering Drugs
title_fullStr The Insulin:Glucagon Ratio and the Choice of Glucose-Lowering Drugs
title_full_unstemmed The Insulin:Glucagon Ratio and the Choice of Glucose-Lowering Drugs
title_short The Insulin:Glucagon Ratio and the Choice of Glucose-Lowering Drugs
title_sort insulin:glucagon ratio and the choice of glucose-lowering drugs
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4801814/
https://www.ncbi.nlm.nih.gov/pubmed/26965024
http://dx.doi.org/10.1007/s13300-016-0160-4
work_keys_str_mv AT kalrasanjay theinsulinglucagonratioandthechoiceofglucoseloweringdrugs
AT guptayashdeep theinsulinglucagonratioandthechoiceofglucoseloweringdrugs
AT kalrasanjay insulinglucagonratioandthechoiceofglucoseloweringdrugs
AT guptayashdeep insulinglucagonratioandthechoiceofglucoseloweringdrugs

Ejemplares similares